AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01254-07v1
52/4/1533    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Smith, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Smith, P. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1533-1537, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01254-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype{triangledown}

Brian T. Tsuji,1,2* Christof von Eiff,3 Pamela A. Kelchlin,1 Alan Forrest,1 and Patrick F. Smith1,2,{dagger}

Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences—Buffalo, and The New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, State University of New York, Buffalo, New York 14260,1 Departments of Pharmacy and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14260,2 Institute of Medical Microbiology, University of Münster, Münster, Germany3

Received 25 September 2007/ Returned for modification 30 October 2007/ Accepted 23 January 2008

The in vitro bactericidal activities of vancomycin against Staphylococcus aureus hemB mutants displaying the small-colony-variant phenotype and their parental strains were evaluated. Vancomycin killing activities against hemB mutants were markedly attenuated, demonstrating approximately 50% less effect, a result which was well described by a Hill-type pharmacodynamic model.

* Corresponding author. Mailing address: School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 331 Cooke Hall, Buffalo, NY 14260. Phone: (716) 881-7543. Fax: (716) 645-2886. E-mail: btsuji{at}buffalo.edu

{triangledown} Published ahead of print on 19 February 2008.

{dagger} Present address: Roche Pharmaceuticals, Nutley, NJ.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1533-1537, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01254-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.